Predicting analysis times in randomized clinical trials

Statistics in Medicine

Volumn 20, Issue 14, 2001, Pages 2055-2063

  Bagiella, Emilia ^a   Heitjan, Daniel F ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOMODULATING AGENT; PLACEBO;

ARTICLE; CHRONIC GRANULOMATOUS DISEASE; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; HUMAN; IMMUNOTHERAPY; INFORMATION PROCESSING; MEDICAL ETHICS; METHODOLOGY; MONITORING; MORTALITY; PREDICTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; STATISTICAL ANALYSIS; STATISTICAL CONCEPTS; STATISTICAL MODEL; STATISTICAL PARAMETERS;

BAYES THEOREM; COMPUTER SIMULATION; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; MODELS, BIOLOGICAL; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS;

EID: 0035974243     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.843     Document Type: Article

References (12)

1. Evaluating therapeutic interventions: Some issues and experiences
2. Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation
3. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance and stratification
4. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease
5. The REMATCH Trial: Rationale, design and endpoints
6. Sample-size formula for the proportional-hazards regression model
7. A multiple testing procedure for clinical trials
8. Group sequential procedures: Calendar versus information time
9. Monitoring clinical trials: Conditional or predictive power?
10. An aid to data monitoring in long-term clinical trials